SCHEMBL278741

SCHEMBL278741

O=C1c2ccccc2C(=O)C2C=CC=CC12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.50
MEN1 O00255 6/20 0.50
S100A4 P26447 3/20 0.50
POLB P06746 2/20 0.50
MAPT P10636 5/20 0.46
TP53 P04637 2/20 0.46
LMNA P02545 2/20 0.46
MAPK1 P28482 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
HTR2B P41595 1/20 0.46
PIM1 P11309 1/20 0.44
CDC25B P30305 1/20 0.41
RAB9A P51151 4/20 0.40
NPC1 O15118 4/20 0.40
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 2/20 0.40
HBB P68871 2/20 0.40
ALOX15 P16050 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29689764 1.00 KMT2A (0.50) KMT2AMEN1S100A4POLBMAPT
SCHEMBL16168528 0.86 MEN1 (0.43) KMT2AMEN1S100A4POLBMAPT
SCHEMBL11966872 0.81 GSTP1 (0.38) KMT2AMEN1S100A4POLBMAPT
SCHEMBL14391531 0.75 PTPRC (0.32) KMT2AMEN1CDC25BPTPRC
SCHEMBL8406222 0.75 CA1 (0.41) KMT2AMEN1POLBMAPTPIM1
SCHEMBL8406221 0.75 ADORA2A (0.44) KMT2AMEN1POLBMAPTLMNA
SCHEMBL24123358 0.75 GSTP1 (0.33) KMT2AMEN1POLBTP53LMNA
SCHEMBL10080214 0.75 TSHR (0.41) KMT2AMEN1S100A4POLBLMNA
SCHEMBL12070597 0.74 USP8 (0.41) KMT2AMEN1S100A4POLBMAPT
SCHEMBL19240498 0.74 MEN1 (0.38) KMT2AMEN1S100A4POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0853618-B1 SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL -AZAHETEROCYCLYLAMIDE COMPOUNDS AVENTIS PHARMA INC (US) 2011-08-17 EP claimed
WO-2024059825-A1 SYSTEMS AND METHODS FOR QUANTIFYING USER OBSERVED VISUALIZATION OF FLUORESCENCE IMAGING AGENTS STRYKER CORPORATION (US) 2024-03-21 WO disclosed
US-20230265231-A1 IMIDE-LINKED POLYMERIC PHOTOINITIATORS ARKEMA FRANCE (FR) 2023-08-24 US disclosed
US-20230265231-A1 IMIDE-LINKED POLYMERIC PHOTOINITIATORS ARKEMA FRANCE (FR) 2023-08-24 US disclosed
US-20220073448-A1 METHOD FOR SYNTHESIZING CARBOXY-CONTAINING ANTHRAQUINONE DERIVATIVE, CARBOXY-CONTAINING ANTHRAQUINONE DERIVATIVE PREPARED THEREBY, AND BATTERY SYSTEM COMPRISING SAME CHINA SALT JINTAN CO., LTD. (CN) 2022-03-10 US disclosed
US-10988810-B2 Methods and materials for detection of mutations PENTABASE APS (DK) 2021-04-27 US disclosed
US-10910634-B2 Electroactive ionic liquids and surface-modified substrates containing them UNIVERSITÉ PARIS CITÉ (FR) 2021-02-02 US disclosed
EP-3453038-B1 ELECTROACTIVE IONIC LIQUIDS AND SURFACE-MODIFIED SUBSTRATES CONTAINING THEM CENTRE NAT RECH SCIENT (FR) 2020-12-16 EP disclosed
US-20200321533-A1 COMPOUNDS FOR ORGANIC LIGHT EMITTING DIODE MATERIALS THE SCRIPPS RESEARCH INSTITUTE 2020-10-08 US disclosed
US-10649330-B2 Resist composition, method of forming resist pattern, compound, and acid generator TOKYO OHKA KOGYO CO., LTD. (JP) 2020-05-12 US disclosed
EP-1701939-B1 ANTHRAQUINONE COMPOUNDS AS ANTI CANCER COMPOUNDS SOMANTA LTD (GB) 2009-02-25 EP disclosed
US-20090044864-A1 ORGANIC PHOTOSENSITIVE OPTOELECTRONIC DEVICES WITH TRIPLET HARVESTING UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2009-02-19 US disclosed
US-20090044864-A1 ORGANIC PHOTOSENSITIVE OPTOELECTRONIC DEVICES WITH TRIPLET HARVESTING UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2009-02-19 US disclosed
US-20080176853-A1 e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders ABRAXIS BIOSCIENCE, INC. (US) 2008-07-24 US disclosed
US-20080176853-A1 e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders ABRAXIS BIOSCIENCE, INC. (US) 2008-07-24 US disclosed
WO-2007104318-A2 OLIGONUCLEOTIDES COMPRISING SIGNALLING PAIRS AND HYDROPHOBIC NUCLEOTIDES, STEMLESS BEACONS, FOR DETECTION OF NUCLEIC ACIDS, METHYLATION STATUS AND MUTANTS OF NUCLEIC ACIDS PENTABASE APS (DK) 2007-09-20 WO disclosed
US-20070161730-A1 Colored thermoplastic resin compositions for laser welding, anthraquinone colorants therefor and molded product therfrom DUPONT POLYMERS, INC. 2007-07-12 US disclosed
US-20070059556-A1 Organic compound and organic light emitting device using the same LG CHEM. LTD. (KR) 2007-03-15 US disclosed
US-20070059556-A1 Organic compound and organic light emitting device using the same LG CHEM. LTD. (KR) 2007-03-15 US disclosed
WO-2006116157-A9 DIPEPTIDYL PEPTIDASE-IV INHIBITORS ALANTOS PHARMACEUTICALS INC (US) 2007-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073448-A1 METHOD FOR SYNTHESIZING CARBOXY-CONTAINING ANTHRAQUINONE DERIVATIVE, CARBOXY-CONTAINING ANTHRAQUINONE DERIVATIVE PREPARED THEREBY, AND BATTERY SYSTEM COMPRISING SAME ACMSD, PROC, AAAS KMT2A 1820/4885MEN1 3058/4885S100A4 241/4885
US-20200321533-A1 COMPOUNDS FOR ORGANIC LIGHT EMITTING DIODE MATERIALS ALDH1A2, DDT, CLTB KMT2A 2223/4885MEN1 2493/4885S100A4 1350/4885
US-10649330-B2 Resist composition, method of forming resist pattern, compound, and acid generator MCM4, RFC4, ATP1A4 KMT2A 2406/4885MEN1 143/4885S100A4 50/4885
US-20070059556-A1 Organic compound and organic light emitting device using the same SLCO4C1, TRPA1, OR51E2 KMT2A 3606/4885MEN1 2364/4885S100A4 3291/4885
US-20080176853-A1 e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders MAP3K15, DSTYK, STK25 KMT2A 790/4885MEN1 2868/4885S100A4 1594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.